For years, Levaquin has been among the most highly-prescribed fluoroquinolone antibiotics, used by patients to treat severe bacterial infections and those that fail to respond to other antibiotics. While the drug is effective in treating ailments such as respiratory tract infections and meningitis, it is also associated with severe adverse reactions, including tendon ruptures.
Indeed, as of this year, the FDA requires that Levaquin packing include a “black box warning” disclosing the serious risk of tendon ruptures resulting from use of the product, especially in those over the age of 60. A “black box warning” is the strongest warning that the FDA requires. The FDA moved to require this warning after being petitioned by public interest groups asking the FDA to require the manufacturers of Levaquin to clearly disclose its risks.
Numerous lawsuits have since been filed against the manufacturers of Levaquin, alleging that for years they failed to adequately disclose the risk of tendon rupture, particularly in the elderly.
If you, or someone you know, have suffered a tendon rupture after use of Levaquin, please contact us to discuss your legal rights.